Utilization of cardiovascular drugs (blood pressure lowering drugs, lipid lowering drugs and nitrates) and mortality from ischaemic heart disease and stroke. An ecological analysis based on Sweden's municipalities

European Journal of Clinical Pharmacology

Volumn 55, Issue 1, 1999, Pages 69-76

  Merlo, J ^a,b   Lindberg, G ^b   Lindblad, U ^a,b,c   Lindgren, A ^a   Rastam L ^a   Melander, A ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Network for Pharmacoepidemiology Foundation   (Sweden)

^c Skaraborgs Institutet   (Sweden)

Author keywords

Cardiovascular drugs; Ischaemic heart disease; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRIC ACID DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DRUG MARKETING; DRUG SAFETY; DRUG UTILIZATION; ECOLOGY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHARMACOEPIDEMIOLOGY; POPULATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEX DIFFERENCE; STROKE; SWEDEN;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR AGENTS; CEREBROVASCULAR DISORDERS; DATA COLLECTION; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MYOCARDIAL ISCHEMIA; NITRATES; SWEDEN;

EID: 0033002652     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050595     Document Type: Article

References (39)

1. Remington RD (1989) Potential impact of exclusion criteria on results of hypertension trials, Hypertension 13 [Suppl I]: I66-I68
2. Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 312: 1215-1218
3. Anonymous (1997) WHO collaborating centre for drugs statistics methodology. Anatomical therapeutical chemical [ATC] classification index. January 1997, Oslo, Norway
4. Capellà D (1993) Descriptive tools and analysis. In: Dukes MNG (ed) Drug utilization studies: methods and uses. WHO regional publication. European series: No. 45. Copenhagen: WHO Regional Office for Europe, pp 55-78
5. Merlo J, Wessling A, Melander A (1996) Comparison of dose standard units for drug utilization studies. Eur J Clin Pharmacol 50: 27-30
6. Francis B, Green M, Payne C (1993) The GLIM system: Release 4 manual. Oxford University Press, Oxford
7. Rothman KJ (1986) Ecological analysis. In: Modern epidemiology. Little, Brown, Boston
8. Rosenbaum PR, Rubin DB (1984) Difficulties with regression analyses of age-adjusted rates. Biometrics 40: 437-443
9. Gibaldi M (1996) Failure to comply: a therapeutic dilemma and the bane of clinical trials. J Clin Pharmacol 36: 674-682
10. Johnson AG, Nguyen TV, Day RO (1994) Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121: 289-300
11. Merlo J, Ranstam J, Liedholm H, Hedblad B, Lindberg G, Lindblad U, Isacsson S-O, Melander A, Råstam L (1996) Incidence of myocardial infarction in elderly men treated with antihypertensive drugs: population based cohort study. BMJ 313: 457-461
12. Frishman WH, Michaelson MD (1997) Use of calcium antagonists in patients with ischemic heart disease and systemic hypertension. Am J Cardiol 79: 33-38
13. Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui T (1990) The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 263: 1653-1657
14. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T (1998) Survival in treated hypertension: follow-up study after two decades. BMJ 317: 167-171
15. Bonita R, Beaglehole R (1989) Increased treatment of hypertension does not explain the decline in stroke mortality in the United States, 1970-1980. Hypertension [Suppl I]: I60-I73
16. Casper M, Wing S, Strogaz D, Davis CE, Tyroler HA (1992) Antihypertensive treatment and US trends in stroke mortality, 1962 to 1980. Am J Public Health 82: 1600-1606
17. Jacobs DR, McGovern PG, Blackburn H (1992) The US decline in stroke mortality; what does ecological analysis tell us? Am J Public Health 82: 1596-1599
18. Whismant JP (1996) Effectiveness versus efficacy of treatment of hypertension for stroke prevention. Neurology 46: 301-307
19. Sytkowsky PA, D'Agostino RB, Belanger AJ, Kannel WB (1996) Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 93: 697-703
20. Anonymous (1996) West of Scotland coronary prevention study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 348: 1339-1342
21. Hebert PR, Gaziano JM, Chan KS, Hennekens CH (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278: 313-321
22. Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, Tsevat J, Weinstein M (1997) The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. JAMA 277: 535-542
23. Thadani U (1996) Secondary preventive potential of nitrates in ischaemic heart disease. Eur Heart J 17 [Suppl F]: 30-36
24. Ishikawa K, Kanamasa K, Ogawa I, Takenaka T, Naito T, Kamata N, Yamamoto T, Nakai S, Hama J, Oyaizu M, Kimura A, Yamamoto K, Aso N, Arai M, Yabushita H, Katori Y (1996) Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Jpn Circ J 60: 779-788
25. Lindblad U, Råstam L, Rydén L (1995) The J-curve phenomenon: inverse relation between achieved diastolic blood pressure and risk of acute myocardial infarction. In: Kendall MJ, Kaplan NM, Horton RC (eds) Difficult hypertension practical management and decision making. Dunitz, London, pp 79-96
26. Strandgaard S (1991) Cerebral blood flow in the elderly: impact of hypertension and antihypertensive treatment. Cardiovasc Drugs Ther 4: 1217-1221
27. Morgenstern H (1998) Ecological studies. In: Rothman KJ, Greenland S [eds] Modern epidemiology, 2nd edn, Lippincott-Raven, Philadelphia, pp 459-480
28. Shapiro S (1997) Confounding by indication? Epidemiology 8: 110-111
29. Feinstein AR (1989) Epidemiologic analysis of causation: the unlearned lessons of randomised trials. J Clin Epidemiol 42: 481-489
30. Petry H, Urquhart J (1991) Channeling bias in the interpretation of drugs effects. Stat Med 10: 577-581
31. Selby JV (1994) Case-control studies of treatment and program efficacy. Epidemiol Rev 16: 90-101
32. Merlo J, Ranstam J, Råstam L, Wessling A, Melander A (1994) Age standardization of drug utilization: comparisons of different methods using cardiovascular drug data from Sweden and Spain. Eur J Clin Pharmacol 46: 393-398
33. Nurminen M (1997) The ecological method: linkage failures and bias correction. In: Corvalan C, Nurminen M, Pastides H, (eds) Linkage methods for environment and health analysis. Technical guidelines. WHO/EHG Geneva
34. Nerbrand C, Kullman S, Schwan A, Alfthan G, Ahola I (1992) Traditional risk factor profile fails to explain striking geographical differences in IHD mortality among middle aged men. The project "myocardial infarction in mid Sweden". Scand J Prim Health Care 10: 111-117
35. Anonymous (1992) Swedish drug statistics 1992. Apoteksbolaget (Swedish National Corporation of Pharmacies) Stockholm, pp 224-229
36. Anonymous (1996) Causes of death and diseases 1996. The national Board of Health and Welfare. Centre for Epidemiology. Article number 1998-42-003
37. Collins R, Peto R (1994) Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD (ed) Textbook of hypertension, Blackwell, Oxford, pp 1156-1164
38. Rosamond WD, Chambless LIE, Folsom AR, Cooper LS, Conwill DE, Clegg L, Wang C-H, Heiss G (1998) Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 339: 861-867
39. Levy D, Thom TJ (1998) Death rates from coronary disease - Progress and a puzzling paradox. N Engl J Med 339: 915-917